Capricorn Energy PLC CNE
Capricorn's board is destroying value by forcing a low-ball NewMed sale; replacing seven directors unlocks up to 400p per share via Palliser's Value Optimisation Plan.
Thesis
Palliser Capital, a 6.96% holder and Capricorn's third-largest shareholder, has requisitioned an EGM to remove seven directors and install six independent nominees with deep oil & gas and Egypt expertise. The firm argues the board has presided over chronic total-shareholder-return underperformance, failed exploration, and woeful capital allocation, culminating in the terminated Tullow merger and now the NewMed transaction, which Palliser says materially undervalues Capricorn and misaligns incentives. Its Value Optimisation Plan — distributing excess cash, monetising UK and Senegal contingent rights via sale or in-specie CVRs, right-sizing G&A and ceasing non-committed exploration, and accelerating PSC optimisation in Egypt — targets up to 400 pence per share of medium-term value. Palliser claims shareholders representing over 28% (four largest) and more than 40% oppose the NewMed deal, supporting drastic board change.
SCQA
Capricorn Energy is a UK-listed E&P with Egyptian production plus UK and Senegal contingent rights, monitored by Palliser for over a decade; Palliser owns 6.96% as third-largest shareholder.
The board oversaw chronic TSR underperformance, failed exploration, the collapsed Tullow merger, and is now pushing the NewMed deal at a value-destructive price despite >40% shareholder opposition.
Vote at the EGM to remove seven incumbent directors, appoint six independent nominees with oil & gas and Egypt expertise, reject NewMed, and adopt Palliser's four-step Value Optimisation Plan.
Palliser's Value Optimisation Plan targets up to 400 pence per share of medium-term value, with further upside from Egyptian licence extensions and improved commercial terms not yet included.
The three reasons
- 1
Board has overseen chronic TSR underperformance and woeful capital allocation
- 2
NewMed deal materially undervalues Capricorn after the failed Tullow merger
- 3
Value Optimisation Plan unlocks up to 400p per share medium-term
Primary demands
- Convene EGM to vote on Resolutions requisitioned by Palliser
- Remove seven current Capricorn directors (Simon Thomson, James Smith, Nicoletta Giadrossi, Peter Kallos, Keith Lough, Luis Araujo, Alison Wood)
- Appoint six independent Director Candidates (Hesham Mekawi, Christopher Cox, Maria Gordon, Craig Van der Laan, Richard Herbert, Tom Pitts)
- Reject the proposed NewMed transaction
- Adopt Palliser's Value Optimisation Plan: distribute excess cash, monetise UK/Senegal contingent rights, cut G&A and halt non-committed exploration, optimise Egypt PSC terms
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Terminated Tullow Oil merger (prior board-backed deal that triggered investor backlash)
- Hesham Mekawi's modernization of BP's Egyptian concessions (nominee track record)
Notable slides (3)
Notes
Short six-page proxy-fight letter (plus Annex 1 statement for inclusion with the EGM Circular) from Palliser Capital's CIO James Smith — note coincidental name clash with Capricorn director James Smith being targeted for removal. Part of a broader campaign (references 9 August and 27 October materials and ReformCapricorn.com) opposing the NewMed transaction, following the earlier collapsed Tullow merger. Document is text-only with Palliser wordmark; no charts or slides. Value Optimisation Plan is summarised as four actionable steps (cash distribution, CVRs, cost discipline, Egypt PSC optimisation) rather than presented with full SoP math here — detailed valuation lives in the 27 October deck.